Efficacy, safety, and cancer-related symptoms in patients with hepatocellular carcinoma with alpha-fetoprotein ≥400 ng/ml: A pooled analysis from REACH and REACH-2 studies - Borbath, I; Kudo, M; Finn, RS; Galle, PR; Llovet, JM; Blanc, J; Okusaka, T; Chau, I; Cella, D; Peck-Radosavljevic, M; Girvan, A; Gable, J; Bowman, L; Abada, P; Hsu, Y; Zhu, AX (Zeitschrift für Gastroenterologie, 2019)